How Big Is the MAB Market | Growth & Trends 2025

Q: What will the MAB market be worth?

The MAB market is expected to surpass USD 415 billion by 2031, driven by strong clinical pipelines, oncology demand, and regulatory approvals.

Q: What innovations are transforming the MAB market?

The MAB market is evolving with bispecific antibodies, ADCs, AI-driven antibody design, and subcutaneous delivery systems that improve patient outcomes.

Q: Which therapeutic areas are driving MAB market growth?

The MAB market is experiencing rapid expansion in oncology, immunology, and infectious diseases due to targeted, effective treatment approaches.

Q: Who are the key players in the MAB market?

Key players in the MAB market include Roche, AbbVie, Amgen, Johnson & Johnson, Eli Lilly, Merck, BMS, and Regeneron—leaders in antibody-based therapies.

Q: How does 6W market outlook report help businesses in making decisions?

6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.

Q: Do you also provide customisation in the market study?

Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

Code: MTA6976

Publication Date: Jul 2025

How Big Is the MAB Market?

According to 6Wresearch internal database and industry insights, the monoclonal antibodies market was valued at USD 230 billion in 2024 and is projected to reach over USD 415 billion by 2031, growing at a CAGR of 8.9%.

The MAB market is growing due to the increasing prevalence of cancers, autoimmune Diseases, and infectious Diseases in addition to an increase in approvals for novel monoclonal antibody therapies. These biologics offer high specificity, fewer side effects, and greater efficacy for these targeted treatment modalities.

Growth Factors of the MAB Market

Rising global burden of cancer, chronic inflammatory, and autoimmune disorders
Expanding R&D investments in immunotherapy and biologics
Increasing FDA and EMA approvals for mAb-based therapies
Growth of personalized medicine and targeted biologics
Advancements in bispecific and antibody-drug conjugates (ADCs)
Strong demand from oncology, rheumatology, and infectious disease sectors

MAB Market Trends

The MAb market is shifting toward biosimilars and subcutaneous formulations for both cost and patient compliance benefits. Pharmaceutical companies are looking to AI for antibody discovery and expediting clinical trials with next-generation biologics. There is also an increasing use of MABs in combination therapies with checkpoint inhibitors and small molecules.

Emerging Developments in the MAB Market

Innovations in the MAB Market include bi-specific and tri-specific antibodies that utilize multiple pathways, long-acting formulations, and cell-free synthesis; companies are effectively applying mRNA and CRISPR technologies to optimize in-process yield (and potential antibody yield in general), and to shorten time-to-market. Additionally, contract manufacturing of monoclonal antibodies is continuing to grow.